To gain a competitive edge, the company partnered with DelveInsight to analyze competitor launch timelines, first-to-market companies, target geographies, commercial preparedness, and salesforce strategies. This comprehensive assessment aimed to optimize market entry strategies and ensure a successful product launch plan.

Drug Launch Analysis offers a detailed evaluation of the launch timelines, regulatory approvals, pricing strategies, and promotional activities. It helps companies assess market readiness and optimize their product positioning for successful market entry.

DelveInsight, a leader in competitive intelligence, provided valuable insights and support for the company's Launch Assessment of Primary Immunodeficiency therapies. Leveraging Primary Intelligence, DelveInsight identified first-to-market competitors, projected launch timelines, and key geographic entry points, equipping the client with actionable insights to refine their go to drug launch strategy.

Primary Immune Deficiency refers to a group of rare, genetic disorders that weaken the immune system, making individuals more susceptible to infections, autoimmune diseases, and other complications. The Immune Deficiency Foundation (IDF) estimates that primary immunodeficiencies (PIs) may affect 1-2% of the global population, with over 6 million people impacted. However, 70-90% of cases remain undiagnosed. More than 430 types of PIDs have been identified, caused by inherited defects in the immune system.